Kendomycin

Kendomycin ((−) -TAN 2162) is a polyketide antibiotic with remarkable antibacterial and cancer cells cytotoxic activities. Kendomycin tends to be bacteriostatic rather than bactericidal and inhibits the growth of the methicillin-resistant Staphylococcus aureus (MRSA) strain COL at a low concentration (MIC of 5 μg/mL) . Kendomycin is a potent antagonist of the endothelin receptor and a calcitonin receptor agonist which plays its role as an anti-osteoporotic agent[1][2].

Product Specifications

CAS Number

[183202-73-5]

Product Name Alternative

(-) -TAN2162

UNSPSC

12352005

Target

Antibiotic; Bacterial; CGRP Receptor; Endothelin Receptor

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/kendomycin.html

Purity

98.00

Solubility

DMSO : 1 mg/mL (ultrasonic; warming)

Smiles

OC(C1=O)=C([C@]([C@@H]([C@H]2O)C)([H])O[C@@](CC[C@@H]3C)([H])[C@@H]2C)C(C(O4)=C1C)=C[C@@]4([C@H](C[C@@H](C/C(C)=C/3)C)C)O

Molecular Formula

C29H42O6

Molecular Weight

486.64

References & Citations

[1] Yasser A Elnakady, et al. Investigations to the Antibacterial Mechanism of Action of Kendomycin. PLoS One. 2016 Jan 21;11 (1) :e0146165.|[2]Yu Yuan, et al. Total synthesis of kendomycin: a macro-C-glycosidation approach. J Am Chem Soc. 2004 Nov 17;126 (45) :14720-1.|[3]Tetsuya Sengoku, et al. Total synthesis of the antibiotic kendomycin: a macrocyclization using the Tsuji-Trost etherification. Angew Chem Int Ed Engl. 2014 Apr 14;53 (16) :4213-6.